WO2020214220A3 - Systèmes cannabinoïdes et procédés : solubilité dans l'eau, ciblage et augmentation - Google Patents

Systèmes cannabinoïdes et procédés : solubilité dans l'eau, ciblage et augmentation Download PDF

Info

Publication number
WO2020214220A3
WO2020214220A3 PCT/US2020/013765 US2020013765W WO2020214220A3 WO 2020214220 A3 WO2020214220 A3 WO 2020214220A3 US 2020013765 W US2020013765 W US 2020013765W WO 2020214220 A3 WO2020214220 A3 WO 2020214220A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
augmentation
targeting
solubility
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/013765
Other languages
English (en)
Other versions
WO2020214220A2 (fr
Inventor
John C. GUSTIN
Michael J. Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2020214220A2 publication Critical patent/WO2020214220A2/fr
Publication of WO2020214220A3 publication Critical patent/WO2020214220A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions, et des procédés associés, comprenant un cannabinoïde fonctionnellement lié à un agent biologiquement actif pour des agents cannabinoïdes augmentés.
PCT/US2020/013765 2019-01-15 2020-01-15 Systèmes cannabinoïdes et procédés : solubilité dans l'eau, ciblage et augmentation Ceased WO2020214220A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962792898P 2019-01-15 2019-01-15
US62/792,898 2019-01-15
US201962803406P 2019-02-08 2019-02-08
US62/803,406 2019-02-08

Publications (2)

Publication Number Publication Date
WO2020214220A2 WO2020214220A2 (fr) 2020-10-22
WO2020214220A3 true WO2020214220A3 (fr) 2020-11-26

Family

ID=72837544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/013765 Ceased WO2020214220A2 (fr) 2019-01-15 2020-01-15 Systèmes cannabinoïdes et procédés : solubilité dans l'eau, ciblage et augmentation

Country Status (1)

Country Link
WO (1) WO2020214220A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045023A4 (fr) * 2019-10-15 2023-09-13 Diverse Biotech, Inc. Molécules conjuguées
US11660348B1 (en) 2022-02-01 2023-05-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
US11883499B2 (en) 2022-02-01 2024-01-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302703A (en) * 1992-04-06 1994-04-12 Biosite Diagnostics Incorporated Tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels
US20150265720A1 (en) * 2014-03-18 2015-09-24 Izun Pharmaceuticals Corp. Water-based cannabinoid and opioid compositions
WO2017183011A1 (fr) * 2016-04-22 2017-10-26 Degeeter David M Complexes d'inclusion hydrosolubles à base de cannabinoïdes
WO2018163187A1 (fr) * 2017-03-09 2018-09-13 Izun Pharmaceuticals Corp. Compositions cannabinoïdes stabilisées, liées à une protéine
US20200254104A1 (en) * 2019-02-11 2020-08-13 John CHANCEY Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disacchride, or monosaccharide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302703A (en) * 1992-04-06 1994-04-12 Biosite Diagnostics Incorporated Tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels
US20150265720A1 (en) * 2014-03-18 2015-09-24 Izun Pharmaceuticals Corp. Water-based cannabinoid and opioid compositions
WO2017183011A1 (fr) * 2016-04-22 2017-10-26 Degeeter David M Complexes d'inclusion hydrosolubles à base de cannabinoïdes
WO2018163187A1 (fr) * 2017-03-09 2018-09-13 Izun Pharmaceuticals Corp. Compositions cannabinoïdes stabilisées, liées à une protéine
US20200254104A1 (en) * 2019-02-11 2020-08-13 John CHANCEY Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disacchride, or monosaccharide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARKOS ET AL.: "Spirulina in Clinical Practice: Evidence-Based Human Applications", EVIDENCE- BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2011, 19 October 2010 (2010-10-19), pages 1 - 4, XP055761656 *
QI ET AL.: "Biomaterials as carrier, barrier and reactor for cell -based regenerative medicine", PROTEIN & CELL, vol. 6, 19 June 2015 (2015-06-19), pages 638 - 653, XP055714765, DOI: 10.1007/s13238-015-0179-8 *

Also Published As

Publication number Publication date
WO2020214220A2 (fr) 2020-10-22

Similar Documents

Publication Publication Date Title
EP4512475A3 (fr) Compositions comprenant un inhibiteur de l'arn polymerase et de la cyclodextrine pour le traitement d'infections virales
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
WO2019002218A3 (fr) Modification de populations microbiennes et modification de microbiote
EP4428234A3 (fr) Procédés, systèmes et compositions de bibliothèque directe
PL2178504T3 (pl) Roztwór oczny na bazie prostagladyn bez środka konserwującego
WO2004064769A3 (fr) Methodes de production et d'utilisation d'agents d'administration topique
WO2019120234A3 (fr) Composé fonctionnant comme inhibiteur de protéine bromodomaine, et composition
EP4093764A4 (fr) Anticorps multispécifiques, compositions comprenant ceux-ci, et vecteurs et utilisations associés
WO2018183692A8 (fr) Vecteurs et compositions pour le traitement d'hémoglobinopathies
WO2018144870A8 (fr) Compositions et méthodes permettant d'inhiber l'inhibiteur reticulon 4
WO2019222400A3 (fr) Peptides pénétrant dans le mucus, véhicules d'administration et méthodes de thérapie
WO2008140469A3 (fr) Compositions antimicrobiennes, procédés et systèmes
USD984527S1 (en) Typeface
WO2020046059A3 (fr) Procédé d'inhibition de la génération de poussière, composition de stabilisateur de sol et dispositif de pulvérisation le comprenant
WO2019195355A9 (fr) Comprimé ou composition à base d'éthanolamine n-acyle et de cannabinoïde
WO2018096525A3 (fr) Composés hétéroaryle et utilisations associées
PL4035528T3 (pl) Związek 7-oksa-3,4-diazabicyklo[4.1.0]hept-4-en-2-onowy i herbicyd
WO2020099736A3 (fr) Agent dispersant osidique
AU2019314696A8 (en) Citrate perhydrates and uses thereof
TW200519126A (en) An antibacterial agent a against propionibacterium acnes
USD989216S1 (en) Anchor peg
WO2023224545A3 (fr) Composés de ciblage de tead et procédés associés
CR20230297A (es) Composición fungicida de ditiocarbamato
WO2020074826A8 (fr) Composition désinfectante a usage topique
IL284549A (en) 5-story air-conditioned exhibition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20792212

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20792212

Country of ref document: EP

Kind code of ref document: A2